Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study

Table 1 Patient demographics and anaesthetic variables

	Nonmonitored group (n = 177)	Monitored group (n = 63)	P value
Age (years)	53.3 ± 17.82	57 ± 16.66	0.15┴
Sex (male/female)	60/117	29/34	0.087*
Body mass index	26.4 ± 5.16	28.1 ± 5.97	0.029┴
ASA physical status (I/II/III/IV)	17/123/37/0	6/36/19/2	0.05^#
Duration of surgery (min)	142.3 ± 67.20	154.8 ± 65.69	0.204┴
NMBD used
Vecuronium	7	1	0.804^#
Atracurium	42	14
Rocuronium	128	48
Interval between last NMBD administration and TOFR measurement (min)	134.43 ± 61.66	105.33 ± 61.08	0.014┴
NMB antagonist, n/total (%)	24/177 (13.5)	51/63 (81)	< 0.01*
Neostigmine	5/24	9/63	< 0.01*
Sugammadex	19/24	42/63	< 0.01*
Dose of NMB antagonist
Neostigmine (μg kg⁻¹)	29.51 ± 9.83	29.64 ± 1.06	0.98┴
Sugammadex (mg kg^− 1)	3.22 ± 1.23	3.90 ± 2.66	0.29┴
RNMB, n/total (%)	57/177 (32%)	1/63 (1.6%)	< 0.001

Data are expressed as the mean ± standard deviation or numbers
ASA American Society of Anesthesiologists, NMB Neuromuscular blockade, NMBD Neuromuscular blocking drug, RNMB Residual neuromuscular blockade, TOFR Train-of-four ratio
┴Student’s t-test
*Chi-square test
#Fisher’s exact test

ISSN: 1471-2253